Table 2.

Summary of activities of ceftobiprole against Gram-positive and Gram-negative species (Adapted from reference [20])

Species	Antimicrobial	MIC (mg/L)			% Susceptibility*
		MIC50	MIC90	MIC range
S. aureus	Ceftobiprole	0.5	2	≤0.03-4	99.7
	Ceftaroline	0.25	2	≤0.06-4	98.5
MRSA	Ceftobiprole	1	2	0.25-4	99.3
	Ceftaroline	0.5	1	0.25-4	96.4
CoNSa	Ceftobiprole	0.5	1	≤0.03-4	100.0
	Ceftaroline	0.25	0.5	≤0.06-2	-c
MRCoNSb	Ceftobiprole	1	1	0.12-4	100.0
	Ceftaroline	0.25	0.5	≤0.06-2	-c
S. pneumoniae	Ceftobiprole	0.015	0.5	0.002-1	99.7
	Ceftaroline	≤0.008	0.12	≤0.008-0.5	99.7
E. faecalis	Ceftobiprole	0.5	2	≤0.03-4	100.0
	Ceftaroline	2	8	≤0.06->8	-c
E. coli	Ceftobiprole	0.03	>16	0.015->16	82.5
	Ceftaroline	0.12	>32	≤0.015->32	78.5
K. pneumoniae	Ceftobiprole	0.03	>16	0.015->16	83.4
	Ceftaroline	0.12	>32	≤0.015->32	80.4
P. aeruginosa	Ceftobiprole	2	16	0.12->16	72.7
	Ceftaroline	16	>32	0.25->32	-c
H. influenzae	Ceftobiprole	0.06	0.12	0.015->1	92.0
	Ceftaroline	0.015	0.03	0.002-2	92.0
M. catarrhalis	Ceftobiprole	0.12	0.25	≤0.008->1	-c
	Ceftaroline	0.12	0.25	0.002-2	-c

^*EUCAST criteria

^acoagulase-negative staphylococci

^bmethicillin-resistant coagulase-negative staphylococci

^cbreakpoints have not been established